Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2017 April;58(2) > The Journal of Cardiovascular Surgery 2017 April;58(2):143-51

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632


eTOC

 

CAROTID ARTERY  HANDLING OF AORTIC AND PERIPHERAL ARTERIAL PATHOLOGIES


The Journal of Cardiovascular Surgery 2017 April;58(2):143-51

DOI: 10.23736/S0021-9509.16.09851-7

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Evidence for periprocedural antiplatelet therapy, heparinization and bridging of coumarin therapy in carotid revascularization

Aarent R. BRAND, Gert J. de BORST

Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands


PDF  


Thromboembolism prevention is a crucial factor determining both the natural outcome and outcome of intervention of stenotic atherosclerotic carotid artery pathology. Roughly 80% of all natural course cerebral ischemic events are caused by thromboembolism, versus 20% due to hemodynamic insufficiency. The risk of periprocedural cerebral (micro-) thromboembolization during carotid revascularization is considered to be even higher, with a higher rate in carotid artery stenting (CAS) as compared to carotid endarterectomy (CEA). Guidelines on CEA and CAS are unanimous in advising perioperative continuation of antiplatelet therapy (APT) for all patients to prevent thromboembolization without specification of the type of APT. Recommendations on dual antiplatelet (DAPT) therapy are inconsistent. Bridging vitamin K antagonists (VKA) perioperative with unfractionated heparin (UFH) or low-molecular weight heparins (LMWHs) might not be necessary for CAS, while CEA-specific data is lacking. No data are available on the use and position of direct-acting oral anticoagulants (DOACs) for CEA or CAS. Guidelines on treatment of carotid artery disease currently do not provide information on perioperative heparinization. There are several monitoring tools to detect perioperative micro-embolic signals during intervention or new cerebral white matter lesions following CEA or CAS. Transcranial Doppler ultrasonography (TDU) and diffusion weighed imaging (DWI) might be used to assess these (secondary) outcome measurements. The use of platelet function testing (PFT) to tailor APT might contribute to finding the therapeutic place of stronger APT and new APT regimen. Periprocedural antiplatelet and anticoagulation therapy for carotid revascularization still lacks solid evidence and guidelines do not yet cover the full spectrum of anticoagulants and procedural steps. This review aims to cover and discuss the full spectrum of available antiplatelet and anticoagulant drugs and therapies available for thromboembolism prevention during all crucial steps of revascularization and specify the need to know topics to be addressed in future research.


KEY WORDS: Carotid revascularization - Perioperative period - Thromboembolism - Platelet aggregation inhibitors - Anticoagulants

top of page

Publication History

Issue published online: February 27, 2017
Article first published online: January 3, 2017

Cite this article as

Brand AR, de Borst GJ. Evidence for periprocedural antiplatelet therapy, heparinization and bridging of coumarin therapy in carotid revascularization. J Cardiovasc Surg 2017;58:143-51. DOI: 10.23736/S0021-9509.16.09851-7

Corresponding author e-mail

g.j.deborst-2@umcutrecht.nl